Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 16 of 16

List	Outcome	Time frame	Description
Primary	Dose-limiting Toxicity(DLT)	28 days	Each dose cohort will initially include 6 evaluable patients for assessment of toxicity within the 28 days following the first dose of nivolumab and GT90001.
Secondary	overall response rate (ORR)	2 years	To estimate ORR, per RECIST 1.1 assessed by investigator review
Secondary	the duration of response (DOR),	2 years	To evaluate the DOR per RECIST 1.1 assessed by investigator review
Secondary	disease control rate (DCR),	2 years	To evaluate the DCR per RECIST 1.1 assessed by investigator review
Secondary	time to response (TTR)	2 years	To evaluate the TTR per RECIST 1.1 assessed by investigator review
Secondary	progression-free survival (PFS)	2 years	To evaluate the PFS per RECIST 1.1 assessed by investigator review
Secondary	maximum concentration (Cmax)	2 years	Pharmacokinetics
Secondary	time that maximum concentration is observed (tmax)	2 years	Pharmacokinetics
Secondary	area under the concentration time-curve from time zero to infinity (AUC0∞)	2 years	Pharmacokinetics
Secondary	area under the plasma concentration-time curve from time zero hours to time (t hrs), (AUC0-t)	2 years	Pharmacokinetics
Secondary	area under the plasma concentration-time curve from time zero hours to 24 hours (AUC0-24)	2 years	Pharmacokinetics
Secondary	terminal elimination rate constant (λz)	2 years	Pharmacokinetics
Secondary	terminal elimination half life (t½)	2 years	Pharmacokinetics
Secondary	volume of distribution (Vz)	2 years	Pharmacokinetics
Secondary	volume of plasma cleared of the drug per unit time (C)	2 years	Pharmacokinetics
Secondary	Exploratory Biomarker: circulating tumor deoxyribonucleic acid (ctDNA)	2 years	HCC-related pathway alterations including VEGF and TGF-β pathway genes

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03893695/registered

API reference For AI assistants